Possibly better effects on fat metabolism (though research is ongoing) thanks to GIPs involvement
This page is not affiliated with, endorsed by, or connected to Novo Nordisk or any manufacturer of semaglutide
At the 12mg dose in Phase 2 trials, participants reported nausea (28%), diarrhea (24%), constipation (21%), and vomiting (17%)
YZ: Data curation, Investigation, Writingoriginal draft
The mechanism likely involves improved insulin sensitivity in the brain, reduced systemic inflammation, and possible dopamine modulation through GLP-1 receptor activation but these effects are inconsistent and not therapeutically reliable
Per the Wegovy Prescribing Information, the typical regimen begins with 0.25 mg weekly for four weeks, increasing monthly through 0.5 mg, 1.0 mg, 1.7 mg, and finally to the target maintenance dose of 2.4 mg weekly